Trials / Completed
CompletedNCT00230529
A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis
A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Infliximab (REMICADE�) Induction Therapy in Patients With Plaque-type Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 249 (actual)
- Sponsor
- Centocor, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with plaque-type psoriasis.
Detailed description
The purpose of this study is to investigate the safety and possible usefulness of infliximab therapy for patients with severe plaque psoriasis. In a previous small study of infliximab in 33 patients with psoriasis, about 80% of patients treated with infliximab showed improvement in their psoriasis symptoms after the first 3 infusions, while 20% of patients who received placebo showed improvement. The patients will receive infusions of infliximab either 3 or 5 mg/kg or placebo at weeks 0,2,6. Patients who have significant psoriasis at week 26 will receive an additional infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | infliximab |
Timeline
- Completion
- 2003-01-01
- First posted
- 2005-10-03
- Last updated
- 2011-06-09
Source: ClinicalTrials.gov record NCT00230529. Inclusion in this directory is not an endorsement.